Physix Frontier · News Briefing Card (enbrief · Nov 21, 2026)

Pharma giants say AI halves early-stage drug discovery timelines

KEY FACTS

  • Seven drugmakers, including GSK, Bristol Myers Squibb and Novartis, said AI is already being used for molecule design and candidate screening.
  • Novo Nordisk said AI cut new-molecule iterations from about eight rounds to three, with each round shrinking from eight weeks to four.
  • Novartis said the time to identify a drug candidate fell from three years to about 18 months to two years, and that it has locked in five kidney-disease targets.
  • Sanofi said AI helped an asthma drug skip one dose study, pulling its timeline forward by at least a year.
  • Statistics show 129 AI-assisted drug candidates from 69 companies are in clinical trials, up from about 117 eight months earlier.

KEY DATA

From about eight rounds to threeNovo Nordisk new-molecule iteration rounds
From three years to about 18 months to two yearsNovartis average time to identify a drug candidate
129 (69 companies)Number of AI-assisted drug candidates in clinical trials
1.5 trillion USDAnthropic IPO valuation

PHYSIX OBSERVATION

AI does deliver speedups in early-stage work such as molecule design, but nearly 90% of drugs still fail in clinical trials, and the efficiency dividend has yet to reach launch success rates. Drugmakers collaborate while fiercely guarding against data leaks, which shows the real moat is proprietary data, not models. With Anthropic entering at a high valuation, the competition has only just begun.

Source: enbrief original report ↗